Mandate

Vinge acts as lead advisor to EQT in connection with its acquisition of Life Sciences Partners

Vinge acts as lead advisor to EQT AB in connection with its acquisition of Life Sciences Partners, a leading European life sciences venture capital firm with approximately EUR 2.2 billion of assets under management

LSP, headquartered in Amsterdam, the Netherlands, is a venture capital firm that invests in innovative companies with strong scientific and clinical rationale across several life sciences strategies. LSP was founded in 1998 and today is one of Europe’s largest and most experienced life sciences investment firms. LSP employs a large number of professionals across its offices in Amsterdam, Munich and Boston. Over the past two decades, LSP has invested in over 150 life sciences companies, generated strong returns, and built a top-performing life sciences franchise. As part of EQT, the LSP team will be able to continue to operate in the same successful manner as they have been operating over the past two decades.

EQT AB will acquire 100 percent of the LSP management companies and 20 percent of the right to carried interest in select LSP funds. In addition, EQT AB will be entitled to 35 percent of the carried interest of future funds. The upfront consideration amounts to EUR 450 million (on a cash- and debt free basis) comprising of 25 percent cash and 75 percent EQT AB publicly traded shares.

Vinge’s team consisted of Christina Kokko, Karl Klackenberg and Milad Kamali (M&A), Sofie Bjärtun (Equity Capital Markets), Emma Johansson and Johan Wahlbom (Competition) and Emma Stuart-Beck and Caroline Krassén (Regulatory) and Ellinor Gyllenhammar (VDR Expert). Vinge has advised EQT together with Debevoise & Plimpton LLP (Investment Funds) and Loyens & Loeff (Dutch law)

Related

Vinge has advised Pareto Securities in connection with a rights issue in Episurf Medical

Vinge has advised Pareto Securities in connection with a partially secured rights issue of units of up to approximately SEK 120 million in Episurf Medical.
April 24, 2024

Vinge has advised Embracer Group in connection with a EUR 900 million bridge facility agreement entered into with JP Morgan, BNP Paribas, SEB, Société Générale and Swedbank

Vinge has advised Embracer Group AB (publ) (“Embracer”) and its subsidiary group Asmodee in connection with the entry into of a EUR 900,000,000 financing agreement with JP Morgan, BNP Paribas, SEB, Société Générale and Swedbank and concurrent prepayment of existing Embracer indebtedness.
April 22, 2024

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024